๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Bone marrow myeloid cell kinetics during treatment of small cell carcinoma of the lung with chemotherapy not associated and associated with granulocyte-macrophage colony-stimulating factor

โœ Scribed by A. Riccardi; M. Danova; A. Paccagnella; M. Giordano; A. Favaretto; M. Panozzo; C. Ghiotto; S. Comis; M. Fiorentino; L. Chieco-Bianchi; E. Ascari

Publisher
Springer
Year
1993
Tongue
English
Weight
914 KB
Volume
66
Category
Article
ISSN
0939-5555

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Dose escalation study of carboplatin wit
Dose escalation study of carboplatin with fixed-dose etoposide plus granulocyte-colony stimulating factor in patients with small cell lung carcinoma: A study of the lung cancer study group of west Japan
โœ Nobuyuki Katakami; Minoru Takada; Shunichi Negoro; Katsuyasu Ota; Jiro Fujita; K ๐Ÿ“‚ Article ๐Ÿ“… 1996 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 738 KB

## BACKGROUND. We performed a Phase 1-11 trial to determine the maximum tolerated dose of carboplatin (CBDCA) with a fixed dose of VP-16 and granulocyte-colony stimulating factor (G-CSF) in small cell lung cancer (SCLC) patients. ## METHODS. Treatment consisted of a starting dose of CBDCA, 400

A phase I clinical and pharmacologic stu
A phase I clinical and pharmacologic study of a carboplatin and irinotecan regimen combined with recombinant human granulocyte-colony stimulating factor in the treatment of patients with advanced nonsmall cell lung carcinoma
โœ Hiroaki Okamoto; Akira Nagatomo; Hideo Kunitoh; Hiroshi Kunikane; Koshiro Watana ๐Ÿ“‚ Article ๐Ÿ“… 1998 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 84 KB ๐Ÿ‘ 3 views

BACKGROUND. This Phase I study was designed to determine the toxicity and efficacy of a carboplatin and irinotecan (CPT-11) regimen with recombinant human granulocyte colony-stimulating factor (rhG-CSF) support for patients with advanced nonsmall cell lung carcinoma. ## METHODS. Treatment consist